91 publications
Name | Date | Type | Actions |
---|---|---|---|
2013 growth driven by reference products Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements. |
12/03/2014 | Public releases | |
2013 annual results SFAF meeting March 13, 2014 |
18/03/2014 | Annual Report | |
Vétoquinol is eligible for new PEA-PME funds Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME |
02/04/2014 | Public releases | |
Reference Document 2013 Reference Document 2013 |
14/04/2014 | Reference document | |
Programme de rachat - mars 2014 (french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
15/04/2014 | Monthly communication regarding buyback programs | |
Monthly information regarding the total number of voting rights and shares making of the share capital - mars 2014 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
15/04/2014 | Voting rights | |
Reference products up 2.2% in Q1 2014 Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
15/04/2014 | Public releases | |
Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction. |
16/04/2014 | Public releases | |
Résultats des cinq derniers exercices |
17/04/2014 | Shareholders´s Meeting | |
Assemblée générale mixte du 13 mai 2014 - exposé des motifs |
17/04/2014 | Shareholders´s Meeting |